The ELN’s stated reasons for this change include the unknown impact of midostaurin with respect to defining AML risk; the increasing role of the presence of MRD in decision-making in the treatment of AML; and, most relevant to this consensus statement, the lack of a standardized method for determining the FLT3-ITD allelic ratio. Here, FLT3 is linked to acute myeloid leukemia.